Oncology Biosimilars Outlook: How Key Stakeholders Can Plan for Change

Posted by ZS Editors on Jul 24, 2017 1:04:28 PM

With the oncology biosimilars market poised for expansion, ZS launched an effort to survey the landscape. Our 2017 Biosimilar Adoption Study polled 252 respondents—including 200 oncologists, 25 payers and 27 pharmacy directors—and the results provide a perspective on market perceptions and other factors that could drive or restrict oncology biosimilars’ adoption. 


>
Read More

Oncology ‘War Games’: Opportunities for Success With Competitive Scenario Workshops

Posted by Christina Corridon on Mar 20, 2017 3:31:04 PM

A decade or so ago, some oncology organizations may have seen a competitive scenario workshop as more of an optional exercise, particularly if they were launching as the first-in-class product to address a high area of unmet need (as was often the case). But times have changed.


>
Read More

Increasing Collaboration to Lower System Cost and Deliver Value: Insights From ASH 2016

Posted by Christina Corridon on Dec 22, 2016 11:13:31 AM

Meadow Green co-wrote this post with Christina Corridon.

In addition to its coverage on value in cancer treatments, the 2016 American Society of Hematology (ASH) Annual Meeting also featured sessions that highlighted how players in a rapidly evolving healthcare delivery ecosystem can collaborate to deliver value and lower system costs.


>
Read More

Driving Treatment Value: Insights From ASH 2016

Posted by Christina Corridon on Dec 21, 2016 9:22:36 AM

Meadow Green co-wrote this post with Christina Corridon.

The 2016 American Society of Hematology (ASH) Annual Meeting was rich with clinical updates and innovations to advance care and improve life for patients with hematologic cancers. However, as life is prolonged among chronic and acute diseases, payers, providers and patients are wrestling with the cost of therapy over months and even years—a topic that came up many times during various sessions at ASH.


>
Read More

Oncology Value Watchdog: What the Oncology Care Model Means for Pharma Marketers

Posted by Christina Corridon on Aug 15, 2016 9:50:43 AM

Marketers in the pharmaceutical industry are no different than those in other industries: They want to understand their customer on multiple dimensions, with accuracy and ideally through low investment. However, oftentimes pharmaceutical marketers’ data sources are limited or fuzzy, and the customer can represent many diverse stakeholders. The entry of the Centers for Medicare and Medicaid Services’ new Oncology Care Model—a payment and delivery model that aims to provide higher-quality, better coordinated oncology care at the same or lower cost to Medicare—provides a clear source of providers participating in the model. Last month, the CMS’ Center for Medicare and Medicaid Innovation (CMMI) released the list of oncology practices and payers selected to participate in the Oncology Care Model. This list is publically available and contains clues as to the makeup and personality of a pharmaceutical customer. In total, 196 practices were selected and will participate in the program over the next few years—more than double what many expected and significantly more than CMMI had previously indicated that they would select. The practices that were selected have been publically enthusiastic and energized to be part of what they see as a transformative program for the delivery of cancer care in a cost-effective manner. Oftentimes, payment reform initiatives and pilots aiming to alter the way that reimbursement for care in the U.S. is delivered are met with opposition and backlash from providers. 


>
Read More